Cannabis Law Report

AUGUST 15, 2021

Creso Pharma’s (CPH) subsidiary, Halucenex, is being awarded a dealer’s licence in Canada, allowing it to advance its clinical trial plans. The licence allows the business to possess, sell, and carry out research on psychedelic substances including psilocybin, ketamine, LSD and MDMA. Shares in CPH are up 7.69

Clinical Trials 105

Clinical Trials Treatment Business 105

Cannabis Law Report

DECEMBER 9, 2021

The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec. Matthew Johnson.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

APRIL 28, 2023

(BUSINESS WIRE)–Biomind Labs Inc.

Clinical Trials 52

Clinical Trials Pharmaceutical Patients Business 52

Cannabis Law Report

AUGUST 7, 2021

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. The right candidate will have a passion for clinical research in novel therapeutics and a proven track record of regulatory affairs experience. Key Responsibilities.

Clinical Trials 105

Clinical Trials Research and Development Compliance Compliance 105

Medical Marijuana Program Connection

JUNE 8, 2023

SAN FRANCISCO–(BUSINESS WIRE)–Defined Research, Inc., a science-based wellness company announces the results of its clinical trial for Defined Sleep, a. Read More

Clinical Trials 40

Clinical Trials Sleep Business CBD 40

Medical Marijuana Program Connection

JUNE 21, 2023

BOSTON–(BUSINESS WIRE)–PureTech Initiates Phase 2a Clinical Trial of LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders Source link. Read More

Clinical Trials 40

Clinical Trials Treatment Business 40

Cannabis Law Report

DECEMBER 14, 2021

–(BUSINESS WIRE)– #IGC –(NYSE American: IGC), India Globalization Capital, Inc. (“IGC” IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease.

Clinical Trials 40

Clinical Trials Safety Data Patients 40

Veriheal

JANUARY 11, 2023

Not only this, but Gaize recently completed the largest clinical trial into cannabis impairment , and the results are set to transform the realm of workplace and road safety. How do you feel about this being the largest cannabis impairment clinical trial ever? Does Gaize plan on carrying out any future clinical trials?

Clinical Trials 98

Clinical Trials THC Data Safety 98

Cannabis Law Report

DECEMBER 27, 2019

Virtual Clinical Trials transcend geographic, mobility and economic barriers. Clinical trials are medical research projects involving human participants. However, the costs of conducting a full-scale clinical trial can be prohibitive, posing barriers to research for cannabis companies.

Clinical Trials 85

Clinical Trials Access Research and Development Supply Chain 85

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Medical Marijuana Program Connection

DECEMBER 6, 2023

–(BUSINESS WIRE)– #AD–IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced an Artificial Intelligence (AI) collaboration with Los Andes University’s Center. POTOMAC, Md.–(BUSINESS Read More

Clinical Trials 49

Clinical Trials Business 49

Cannabis Law Report

DECEMBER 2, 2021

–(BUSINESS WIRE)– #Alzheimers –(NYSE American: IGC), India Globalization Capital, Inc. IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The details of a clinical trial process in general are documented in IGC’s annual report.

Clinical Trials 40

Clinical Trials Data Patients THC 40

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

APRIL 12, 2021

– Vaccine Candidate Well Tolerated and Effective in Cohort – – Strong Neutralizing Antibody Titer Elicited Across Cohort – STONY… Read More.

Clinical Trials 75

Clinical Trials Business 75

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

OCTOBER 6, 2021

MIAMI & TORONTO–(BUSINESS WIRE)–Flora Growth Corp. NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has signed an agreement to begin scientific clinical trials globally. About Flora Growth Corp.

Clinical Trials 40

Clinical Trials Research and Development Pharmaceutical Events 40

Cannabis Law Report

AUGUST 3, 2021

TORONTO–( BUSINESS WIRE )– Cybin Inc. Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. The Neo Exchange Inc. Investor Contacts : Tim Regan/Scott Eckstein.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Cannabis Law Report

JANUARY 4, 2022

& LOS ANGELES–(BUSINESS WIRE)– ANANDA Scientific Inc., (a Funding for this trial is from the National Institute on Drug Abuse (NIDA). Clinical Trials.gov Identifier: NCT03787628 ). With the IND approved we are now moving quickly to get the trial under way,” said Dr. GREENWOOD VILLAGE, Colo. &

Clinical Trials 40

Clinical Trials Treatment Research and Development Media 40

Cannabis Law Report

AUGUST 9, 2021

Investors will continue to keep an eye on several ongoing clinical trials, as well as private companies that are gearing up to go public over the coming quarters. via Business Insider. The PsyIndex extended its move lower over the past week, even as two companies moved to senior stock exchanges. Market Performance. Powered by.

Clinical Trials 105

Clinical Trials Decriminalization Research and Development Treatment 105

Cannabis Law Report

SEPTEMBER 13, 2021

Key objective of the trial is to reduce levels of the protein that causes inflammation and activates aging, TNF-?, BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. in the blood. MYMD-1 is designed to become the first and only FDA-approved therapeutic solution for delaying aging and prolonging lifespan. in the blood.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Therapy 40

Cannabis Law Report

DECEMBER 20, 2021

–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., BERWYN, Pa.–(BUSINESS

Clinical Trials 40

Clinical Trials Chronic Pain Pharmaceutical Data 40

Cannabis Law Report

AUGUST 10, 2021

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. (“Shanti”), and all its assets focused on psychedelic MDMA-based drug development. from 2020 to 2030 and generate revenue of $151.7

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Cannabis Law Report

AUGUST 2, 2021

capital markets, negative global economic conditions, potential negative developments in our clinical trials or research programs, other negative developments in our business, or unfavorable legislative or regulatory developments. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co.,

Clinical Trials 105

Clinical Trials Research and Development Treatment Conditions 105

Cannabis Law Report

AUGUST 17, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Orphan drug designation provides certain benefits, including market exclusivity upon regulatory approval, if received, exemption of FDA application fees and tax credits for qualified clinical trials. RADNOR, Pa.–(BUSINESS

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

Medical Marijuana Program Connection

JANUARY 31, 2023

DUBLIN–(BUSINESS WIRE)–The “Medical Cannabis Market: Global Market Size, Forecast, Insights, and Competitive Landscape” report has been added to ResearchAndMarkets.com’s offering. Read More

Clinical Trials 52

Clinical Trials Business Cannabis 52

Cannabis Law Report

AUGUST 12, 2021

11, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2021 and gave an update on recent progress across its business. Business highlights. LONDON, Aug.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

JULY 8, 2021

Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the impact of the novel coronavirus (COVID-19) on Enveric’s ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on Enveric’s ability to conduct (..)

Treatment 98

Treatment Clinical Trials CBD Patients 98

Cannabis Law Report

SEPTEMBER 9, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.

Pharmaceutical 74

Pharmaceutical Clinical Trials Chronic Pain Epilepsy 74

Cannabis Law Report

NOVEMBER 12, 2021

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. Completed manufacturing of ANEB-001 capsules for upcoming Phase 2 clinical trial. On track to commence Phase 2 proof-of-concept clinical trial with ANEB-001 for the treatment of acute cannabinoid intoxication by year-end.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Medical Marijuana Program Connection

JANUARY 20, 2023

SAN FRANCISCO–(BUSINESS WIRE)–Teon Therapeutics (Teon), a clinical-stage biopharmaceutical company targeting metabolic signaling pathways and pioneering the development of G-Protein Coupled. Read More

Clinical Trials 52

Clinical Trials Business 52

Cannabis Law Report

SEPTEMBER 29, 2021

& LOS ANGELES–(BUSINESS WIRE)– ANANDA Scientific Inc. , GREENWOOD VILLAGE, Colo. &

Clinical Trials 40

Clinical Trials Medicine Treatment Research and Development 40

Medical Marijuana Program Connection

DECEMBER 5, 2023

SASKATOON, Saskatchewan–(BUSINESS WIRE)– #Phase2–ZYUS Life Sciences Corporation (“ZYUS” or the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of. Read More

Clinical Trials 45

Clinical Trials Research and Development Business 45

MGC Pharma

FEBRUARY 20, 2018

The Top Medical Cannabis Research of 2017 A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals MGC Pharma is still riding off the success of 2017 as we progress into 2018, with many exciting developments on the horizon.

Research and Development 100

Research and Development Clinical Trials Patients Chronic Pain 100

Cannabis Law Report

JULY 26, 2021

Tyle brings over 35 years of experience in the pharmaceutical industry, with over 37 years in senior executive leadership positions encompassing research and development, clinical development, manufacturing, regulatory, business development and operations as well as roles as a board director and scientific advisory board member.

Research and Development 105

Research and Development Clinical Trials Pharmaceutical Cannabinoids 105

Medical Marijuana Program Connection

JANUARY 2, 2024

–(BUSINESS WIRE)—- $LBPH #DEEs–Longboard Pharmaceuticals, Inc. LA JOLLA, Calif.–(BUSINESS

Pharmaceutical 53

Pharmaceutical Clinical Trials Data Medicine 53

Medical Marijuana Program Connection

DECEMBER 6, 2023

BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc.® ® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and. Read More

Clinical Trials 40

Clinical Trials Pharmaceutical Therapy Business 40